Where is that in terms of FDA approval?
Ms. Park: None of our products have proceeded to FDA approval. Because of the downturn in the economy and the fact that we had to reduce the size of the company for space and personnel, we have put all of our resources into neurodegenerative disease. The breast cancer test at this time is halted in clinical validation trial Phase I. We are pursuing partners to move ahead. TWST: What do you consider your competitive advantage? Ms. Park: Our competitive advantage is that we can distinguish between the controls and the disease by using more specific biomarkers, which actually indicate the disease mechanisms and the fact that we are looking at biomarkers that are directly related to what the neurologists would want to see as far as what the disease is doing to the patient. In other words, you can have a genetic test for a disease and it might say, “Oh we think you might have a higher risk of getting this,” but we can look directly at the diseased cell proteins being released into the serum
